Literature DB >> 32958524

Development of Novel, Value-Based, Digital Endpoints for Clinical Trials: A Structured Approach Toward Fit-for-Purpose Validation.

M D Kruizinga1, F E Stuurman1, V Exadaktylos1, R J Doll1, D T Stephenson1, G J Groeneveld1, G J A Driessen1, A F Cohen2.   

Abstract

Novel digital endpoints gathered via wearables, small devices, or algorithms hold great promise for clinical trials. However, implementation has been slow because of a lack of guidelines regarding the validation process of these new measurements. In this paper, we propose a pragmatic approach toward selection and fit-for-purpose validation of digital endpoints. Measurements should be value-based, meaning the measurements should directly measure or be associated with meaningful outcomes for patients. Devices should be assessed regarding technological validity. Most importantly, a rigorous clinical validation process should appraise the tolerability, difference between patients and controls, repeatability, detection of clinical events, and correlation with traditional endpoints. When technically and clinically fit-for-purpose, case building in interventional clinical trials starts to generate evidence regarding the response to new or existing health-care interventions. This process may lead to the digital endpoint replacing traditional endpoints, such as clinical rating scales or questionnaires in clinical trials. We recommend initiating more data-sharing collaborations to prevent unnecessary duplication of research and integration of value-based measurements in clinical care to enhance acceptance by health-care professionals. Finally, we invite researchers and regulators to adopt this approach to ensure a timely implementation of digital measurements and value-based thinking in clinical trial design and health care. SIGNIFICANCE STATEMENT: Novel digital endpoints are often cited as promising for the clinical trial of the future. However, clear validation guidelines are lacking in the literature. This paper contains pragmatic criteria for the selection, technical validation, and clinical validation of novel digital endpoints and provides recommendations for future work and collaboration.
Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32958524     DOI: 10.1124/pr.120.000028

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  11 in total

1.  Objective Home-Monitoring of Physical Activity, Cardiovascular Parameters, and Sleep in Pediatric Obesity.

Authors:  Janine M Knijff; Euphemia C A M Houdijk; Daniëlle C M van der Kaay; Youri van Berkel; Luc Filippini; Frederik E Stuurman; Adam F Cohen; Gertjan J A Driessen; Matthijs D Kruizinga
Journal:  Digit Biomark       Date:  2022-03-31

Review 2.  Digital Biomarkers in Psychiatric Research: Data Protection Qualifications in a Complex Ecosystem.

Authors:  Andrea Parziale; Deborah Mascalzoni
Journal:  Front Psychiatry       Date:  2022-06-09       Impact factor: 5.435

3.  Postdischarge Recovery after Acute Pediatric Lung Disease Can Be Quantified with Digital Biomarkers.

Authors:  Matthijs D Kruizinga; Allison Moll; Ahnjili Zhuparris; Dimitrios Ziagkos; Frederik E Stuurman; Marianne Nuijsink; Adam F Cohen; Gertjan J A Driessen
Journal:  Respiration       Date:  2021-05-18       Impact factor: 3.580

Review 4.  Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science.

Authors:  Diane Stephenson; Robert Alexander; Varun Aggarwal; Reham Badawy; Lisa Bain; Roopal Bhatnagar; Bastiaan R Bloem; Babak Boroojerdi; Jackson Burton; Jesse M Cedarbaum; Josh Cosman; David T Dexter; Marissa Dockendorf; E Ray Dorsey; Ariel V Dowling; Luc J W Evers; Katherine Fisher; Mark Frasier; Luis Garcia-Gancedo; Jennifer C Goldsack; Derek Hill; Janice Hitchcock; Michele T Hu; Michael P Lawton; Susan J Lee; Michael Lindemann; Ken Marek; Nitin Mehrotra; Marjan J Meinders; Michael Minchik; Lauren Oliva; Klaus Romero; George Roussos; Robert Rubens; Sakshi Sadar; Joseph Scheeren; Eiichi Sengoku; Tanya Simuni; Glenn Stebbins; Kirsten I Taylor; Beatrice Yang; Neta Zach
Journal:  Digit Biomark       Date:  2020-11-26

5.  Towards remote monitoring in pediatric care and clinical trials-Tolerability, repeatability and reference values of candidate digital endpoints derived from physical activity, heart rate and sleep in healthy children.

Authors:  M D Kruizinga; N van der Heide; A Moll; A Zhuparris; Y Yavuz; M L de Kam; F E Stuurman; A F Cohen; G J A Driessen
Journal:  PLoS One       Date:  2021-01-07       Impact factor: 3.240

Review 6.  Factors Determining Plasticity of Responses to Drugs.

Authors:  Michael J Parnham; Jennifer A Kricker
Journal:  Int J Mol Sci       Date:  2022-02-13       Impact factor: 5.923

7.  Development and technical validation of a smartphone-based pediatric cough detection algorithm.

Authors:  Matthijs D Kruizinga; Ahnjili Zhuparris; Eva Dessing; Fas J Krol; Arwen J Sprij; Robert-Jan Doll; Frederik E Stuurman; Vasileios Exadaktylos; Gertjan J A Driessen; Adam F Cohen
Journal:  Pediatr Pulmonol       Date:  2022-01-11

Review 8.  The economic imperatives for technology enabled wellness centered healthcare.

Authors:  Graham B Jones; Justin M Wright
Journal:  J Public Health Policy       Date:  2022-08-03       Impact factor: 3.526

Review 9.  Translational precision medicine: an industry perspective.

Authors:  Dominik Hartl; Valeria de Luca; Anna Kostikova; Jason Laramie; Scott Kennedy; Enrico Ferrero; Richard Siegel; Martin Fink; Sohail Ahmed; John Millholland; Alexander Schuhmacher; Markus Hinder; Luca Piali; Adrian Roth
Journal:  J Transl Med       Date:  2021-06-05       Impact factor: 5.531

10.  Accelerating vaccine trial conduct in a pandemic with a hot spot-based inclusion strategy using trial and epidemic simulation.

Authors:  Johan L van der Plas; Michiel J van Esdonk; Ingrid M C Kamerling; Adam F Cohen
Journal:  Clin Transl Sci       Date:  2021-07-14       Impact factor: 4.438

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.